Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults

. Author manuscript; available in PMC: 2015 Aug 13.

Published in final edited form as: Cochrane Database Syst Rev. 2014 Aug 13;8:CD003256. doi: 10.1002/14651858.CD003256.pub2

HAART + pegylated liposomal doxorubicin compared to HAART + liposomal daunorubicin for the treatment of severe Kaposi's sarcoma in HIV-infected adults (Cooley 2007) – RCT

Patient or population: HIV-infected adults with severe (T1) Kaposi's sarcoma

Settings: USA

Intervention: HAART + pegylated liposomal doxorubicin

Comparison: HAART + liposomal daunorubicin

Outcomes	Illustrative comparative risks^* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk
	HAART + liposomal daunorubicin	HAART + PLD
Progression of Kaposi's sarcoma	See comment	See comment	Not estimable	46 (1 study)	⊕⊕⊕◯ moderate¹

The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; HAART: highly active antiretroviral therapy; PLD: pegylated liposomal doxorubicin; RCT: randomised controlled trial; RR: risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

There were very few events with very wide confidence intervals.